MLKL and myelodysplastic syndrome: Poor correlation between an IFN response and the outcome of 5-AZA therapy is also suggested by a recent study reporting higher expression of the necroptosis mediator MLKL in untreated MDS and CMML HSCs than in healthy HSCs [65].